Levocetirizine Viatris

Levocetirizine dihydrochloride, the active ingredient in Levocetirizine Viatris, is a second‑generation antihistamine presented as an oral tablet for oral use. It is indicated for the relief of symptoms associated with allergic rhinitis and chronic idiopathic urticaria in adults and adolescents.

GNH USA supplies Levocetirizine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Levocetirizine acts as a selective peripheral H1‑receptor antagonist to manage allergic conditions.

Allergic rhinitis: reduces nasal congestion, sneezing, itching and rhinorrhea. Seasonal allergic rhinitis: provides symptom control during pollen seasons. Chronic idiopathic urticaria: alleviates wheals and itching associated with chronic hives.

Levocetirizine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Drowsiness or mild sedation - Headache - Dry mouth - Fatigue - Nausea - Abdominal discomfort

Serious or Rare Side Effects: - Angioedema or swelling of the face, lips, tongue - Anaphylactic reactions - Severe skin reactions such as Stevens‑Johnson syndrome - Tachycardia or palpitations - Hepatic enzyme elevations - Hematologic abnormalities (e.g., neutropenia, thrombocytopenia)

Before initiating therapy, consider the following precautions.

Renal impairment: dose may require adjustment in severe renal dysfunction. Hepatic impairment: use with caution; monitor liver function tests. Elderly patients: increased sensitivity to sedation; monitor for falls. Pregnancy and lactation: safety not fully established; discuss risks with a healthcare professional. Driving or operating machinery: may cause drowsiness; avoid hazardous tasks until individual response is known. Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Levocetirizine may interact with other medicines; monitor accordingly.

Major Interactions (Avoid): - Alcohol: additive central nervous system depression. - CNS depressants (e.g., benzodiazepines, opioids): increased sedation. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise levocetirizine plasma levels.

Moderate Interactions (Monitor Closely): - Theophylline: potential increase in theophylline concentrations. - Ritonavir or other protease inhibitors: may elevate levocetirizine exposure. - Concurrent antihistamines: risk of cumulative anticholinergic effects.